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Chapter I 
 
Quantum Dot Flow Cytometry in Structure-Activity Relationship Study of 
Optimized Human Serotonin Transporter Ligands  
 
 
 
INTRODUCTION 
Major depression is a debilitating and recurrent disorder with a substantial 
lifetime risk and a high social cost.
1
  At any given time, depression has been shown to 
affect nearly 18 million people in the United States alone.
2
 Over the past 30 years, 
numerous studies of the serotonin (5-Hydroxytryptophan, 5-HT) system and one of its 
principal components, serotonin transporter (SERT) protein, have reinforced the 
significant role of the serotonergic pathway in pathophysiology of major depression.3  In 
particular, disrupted SERT cellular localization and regulation have been implicated in 
multiple neuropsychiatric disorders, including anxiety, depression and autism.
1,3
  The 
presynaptic serotonin transporter regulates synaptic levels of 5-HT by recycling it into the 
presynaptic terminals in the brain.
4
  Low synaptic 5-HT levels have been shown to induce 
depressive symptoms, such as mood swings, fatigue, anxiety, and suicidal tendencies.  To 
treat these symptoms, selective serotonin reuptake inhibitors (SSRIs) are widely used as 
clinical antidepressants.  One of the major challenges associated with the discovery of 
new, more efficacious antidepressants is the lack of a resolved crystal structure of the 
serotonin transporter.  At present, methods to investigate SERT activity include mainly 
conventional biochemical and radiolabeling approaches such as phosphorylation assays, 
electrophysiology, or radio-isotope substrate uptake assays.
5
  The disadvantages of these 
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methods include time-consuming, labor-intensive experimental work, poor 
spatiotemporal resolution, and safety concerns associated with isotope handling.
1 
As an alternative, fluorescent probes can be used for target selective drug 
screening of membrane transporter proteins.  The live-cell labeling, tracking and dynamic 
investigations of hSERT, and other membrane proteins, pose complications when studied 
due to important challenges.  Typically, antibody-based labeling approach is utilized to 
detect single membrane proteins;
6-7
 however, many proteins lack suitable extracellular 
domains that can be targeted by antibodies without functional disruption.  Furthermore, 
the use of popular fusion tags to label membrane proteins, usually consisting of a short 
peptide sequence with a recognition epitope for a complementary binding partner, such as 
hemagglutinin (HA), requires genetic perturbation of the protein target
8
 and thus does not 
allow direct visualization of endogenous protein of interest.   
The Rosenthal group has pioneered the use of organic ligands conjugated to 
quantum dots to target cell surface membrane proteins.
9,10
  Organic ligands can achieve 
specific targeting of transporter proteins, which allows visualization of endogenous 
protein without the functional disruption of the protein of interest. Quantum dots (QDs), 
nanometer-sized semiconductor nanocrystals, exhibit excellent photostability and 
brightness, which allow for long-term imaging of biological systems.9,10 Also, their broad 
absorption spectra and size-dependent, narrow, symmetric emission spectra of QDs 
considerably simplify multiplexed, molecular imaging experiments.  Based on the 
structure of the cell surface protein, the organic ligand can be tailored with a linker arm to 
optimize QD conjugate binding to the target protein.
8,10
  The ability to find the structural 
requirements for optimal binding activity can be achieved by molecular modeling.  The 
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molecular modeling of an organic ligand saves time by eliminating unnecessary organic 
chemistry synthesis and reveals an optimized ligand design for the protein of interest. 
Even though, the serotonin transporter crystal structure has not been determined, a 
homology model has been created based upon the crystal structure of LeuTaq as a 
template.
11-13
  The homology model of hSERT provides a structure to computationally 
dock ligands with RosettaLigand.
11-13
 In the following structure-activity relationship 
study, we have investigated how subtle modifications of the selected SERT ligands can 
lead to dramatic changes in binding affinity and selectivity towards the SERT protein.  
Recently, we reported the synthesis of probes of the human serotonin transporter where 
an alkyl spacer was attached to high affinity SERT antagonist, followed by the 
subsequent conjugation of a biotinylated, polyethylene glycol chain.14 These synthesized 
SERT ligands are amenable to conjugation to streptavidin coated QDs via the biotin-
streptavidin binding interaction.  The affinities of these SERT ligands were measured by 
their ability to produce SERT-dependent currents in Xenopus laveis oocytes.  Even 
though these SERT ligands were found to bind to the SERT protein of interest, no insight 
into the ideal alkyl space in linker arm needed for the SERT membrane protein binding 
has been provided. 
Here, RosettaLigand computer modeling software provides insight into the 
structural-activity relationship of SERT protein and would allow for faster optimized 
ligand design of an ideal alkyl space in linker arm.  RosettaLigand is a premiere 
algorithm that has proven successful docking of ligands into crystal structures.  The 
RosettaLigand program rapidly docks multiple conformations of ligands into crystal 
structures. This process can be used in conjunction with the homology hSERT model to 
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dock known substrates and inhibitors.  In this study, 3-(1,2,3,6-tetrahydropyrindin-4-yl)-
1H-indole and its cyano derivative, 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-5-
carbonitrile, have been docked into the homologous model of hSERT using 
RosettaLigand.  Using docking studies of the SERT model, we investigated the length of 
alkyl spacer in the linker arm of the organic ligands, using 2, 6, 7, 8, or 11 alkyl spacer 
lengths, and the effect of binding in both ligand models (Figure 1).   
To validate the modeling, QD flow cytometry-based assay measuring 
fluorescence of ligand binding was done to demonstrate and confirm that structural 
modeling can optimize length of the organic ligand linker arm design and synthesis.   
EXPERIMENTAL 
RosettaLigand Computer Modeling 
Parent drugs were designed using the Molecular Environment (MOE) 2009 
application. Ten conformations were generated for each drug with an RMSD ≥ 0.5A. The 
parent drug was then placed in the binding pocket of hSERT overlapping the known 
binding site of 5-HT. The ligand was then docked using RosettaLigand confined to 5A 
movement from its initial location, generating 5000 output complexes. The top ten 
  
VS 
Figure 1. Structures of the 3-(1,2,3,6-tetrahydropyrindin-4-yl)-1H-indole ligands and its cyano 
derivative, 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-5-carbonitrile ligands. 
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scoring complexes, based on the overall RosettaLigand score, were used for further 
evaluation. 
An alkyl spacer was built one carbon at a time, spanning from one to eleven 
carbons, by sequentially adding one methyl group to the N-terminus of the ligand. Ten 
conformations were generated for each ligand by holding the previously docked complex 
in place (only the newly added methyl group was allowed to move freely for 
conformation generation).  The compounds were then docked using RosettaLigand 
confined to 1.5Ǻ of their original location in the binding pocket, generating 5000 output 
complexes per ligand. The top five scoring complexes were then evaluated and used in 
sequential alkyl spacer addition. 
In order to determine whether or not the alkyl spacer of the ligand accurately 
spans the hydrophobic region of hSERT, a heatmap of the protein was generated. This 
heat map scores each residue of the protein and, among other things, predicts which 
region of the protein (hydrophobic, transition or hydrophillic) the residue is most likely to 
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reside in. Residues predicted to be in the transition region of the protein were used to 
generate a plane which served as the protein's transition region. The residues chosen were 
Arg104, Ile179, and Tyr495 (Figure 2). 
Cell Line Maintenance and hSERT Activity Assay 
The hSERT stably transfected HEK293T host cell line was provided by Dr. 
Randy Blakely’s lab (Vanderbilt University) and was grown in complete DMEM, 
supplemented with 10% dialyzed  FBS and incubated in humidified atmosphere with 5% 
CO2 at 37°C.  The SERT-expressing HEK293T cells were selected in the presence of 400 
μg/mL G418. 
The SERT protein activity in living HEK293T cells was examined before each 
experiment by using IDT307, a fluorescent neurotransmitter substrate.
15
  IDT307 
compound is nonfluorescent in solution but fluoresces as the substrate is accumulated 
into the nucleus membrane, affording real-time evaluation of SERT uptake activity.
15
  
The assay to verify successful SERT expression in HEK293T cells involves the addition 
of IDT307 directly to the culture media at a final concentration of 5 μM and incubating at 
37°C for 10 minutes. Fluorescent images were then acquired immediately after IDT307 
addition, and successful transporter expression was evident by an observable increase in 
intracellular fluorescence (see Figure 3).  
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Labeling HEK293T Cells with Ligand-Conjugated Quantum Dots for Fluorescent 
Microscopy 
The stably transfected hSERT-expressing HEK293T cells were treated using a 
two-step quantum dot, Qdot® 655 streptavidin conjugate (Invitrogen
TM
), labeling 
protocol.  Previously before flow cytometry experiments, SERT-expressing HEK293T 
cells were seeded MatTek (MetTek Corporation) polylysine-coated plates and were 
allowed to grow for approximately 48hours at 37
o
C and 5%CO2. 
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Adherent SERT-expressing (1) competition control cells were pre-blocked by 
exposure to 10 μM of Paroxetine and incubated for 10 minutes at 5% CO2 / 37°C, (2) 
competition control, wild type, and positive cells were incubated with 0.5μM SERT 
ligands with inhibitor mixture for 10 min for all sample types, (3) washed several times 
with DMEM free media and incubated with 1 nM SavQD655/1% BSA (bovine serum 
albumin) mixture, (4) After the SavQD655 labeling step, HEK cells were washed with 
DMEM free media to remove any unbound SavQD655 and cells images were acquired 
on the Zeiss Laser Scannin Microscope 510 inverted confocal microscope.  
Representative images of hSERT-HEK293T or HEK293T cells exposed to two-step QD 
labeling protocol using the ligand, IDT357 can be seen in Figure 4. 
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Labeling HEK293T Cells with Ligand-Conjugated Quantum Dots for Flow 
Cytometry 
The stably transfected hSERT-expressing HEK293T cells were treated using a 
two-step quantum dot, Qdot® 655 streptavidin conjugate (Invitrogen
TM
), labeling 
protocol.  Previously before flow cytometry experiments, SERT-expressing HEK293T 
cells were seeded in 24-well polylysine-coated plates (BD Bioscience®) and were 
allowed to grow for approximately 48hours at 5% CO2 / 37°C. 
Next, a flow cytometry-based probe screening protocol was established that 
would allow multi-well plate screening of both adherent and suspension cell cultures 
using our ligand-conjugated SavQDs. The screening platform is depicted in Figure 5. 
Adherent SERT-expressing (1) competition control cells were pre-blocked by exposure to 
10 μM of Paroxetine, a potent and selective serotonin reuptake inhibitor (SSRI), and 
incubated for 10 minutes at 5% CO2 / 37°C, (2) competition control, wildtype, and 
positive cells were incubated with 0.5μM SERT ligands with inhibitor mixture for 10 min 
for all sample types, (3) washed several times with DMEM free media and incubated 
with 1 nM SavQD655/1% BSA (bovine serum albumin) mixture, (4) nonenzymatically  
dissociated (Cellstripper™), and (5) assayed by flow cytometry.  Before each 
fluorescence measurement are obtained, the voltage of the 5-laser BD LSRII cytometer 
are adjusted by using Attune™ Performance tracking or calibration beads (Applied 
Biosystems®).  
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Figure 5. Schematic of a QD-based assay that investigates the length of alkyl spacer in the linker arm of 
the organic ligands, using 2, 6, 7, 8, or 11 alkyl spacer lengths, and the effect of binding in ligand 
models. Adherent SERT-expressing (1) competition control cells were exposed to 10 μM of Paroxetine, 
a potent and selective serotonin reuptake inhibitor (SSRI), and incubated for 10 minutes at 5% CO2 / 
37°C, (2) competition control, wildtype, and positive cells were incubated with 0.5μM SERT probes 
with inhibitor mixture for 10 min for all sample types, (3) washed several times with DMEM free media 
and incubated with 1 nM SavQD655/1% BSA (bovine serum albumin) mixture, (4) nonenzymatically  
dissociated (Cellstripper™), and (5) assayed by flow cytometry.  
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Obtained fluorescence percent data were pooled from five independent 
experiments with triplicate samples to generate average percent fluorescent intensities of 
each of the cyano group ligands or indole (hydrogen) ligands (Figure 1).  The heat map, 
representative histogram plots, and data tables were generated using average percent 
fluorescent intensity values pooled from five independent experiments with triplicate 
samples of each ligand subtype (Figure 6). 
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3-(1,2,3,6-tetrahydropyrindin-4-yl)-1H-indole Ligands 
Figure 6. Screening of stably transfected hSERT-expressing HEK293T cell line to investigate the 
effect of length of alkyl spacer in the linker arm, using 2, 6, 7, 8, or 11 alkyl spacers.  The heat map 
and representative histogram plots of the effects of increasing the alkyl spacer length on QD 
conjugate binding are shown. The heat map and representative histogram plots were generated using 
average percent fluorescent intensity values pooled from five independent experiments with triplicate 
samples of each ligand subtype. 
3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-5-carbonitrile Ligands 
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RESULTS AND DISCUSSION 
The stably transfected hSERT-expressing HEK293T cell line was used as a model 
system to investigate the effect of the length of alkyl spacer in the linker arm on binding, 
using 2, 6, 7, 8, or 11 alkyl spacer lengths.   The effect length of alkyl spacer in the linker 
arm on ligand binding were compared in both ligand models containing the 3-(1,2,3,6-
tetrahydropyrindin-4-yl)-1H-indole drug end and its cyano derivative ligand, 3-(1,2,3,6-
tetrahydropyridin-4-yl)-1H-indole-5-carbonitrile. 
The serotonin transporter expression level in living HEK293T cells was examined 
before each flow cytometry experiment by using IDT307, a fluorescent monoamine 
neurotransmitter transporter substrate.  Representative images of hSERT-HEK293T or 
HEK293T cells after exposure to IDT307 are shown in Figure 3. Intracellular 
accumulation of IDT307 by functional membrane SERTs (Figure 3:A1, A2) resulted in a 
characteristic mitochondria- and nucleoli-associated fluorescence.  In contrast, the 
HEK293T (Wildtype) cells (Figure 3:B1, B2) demonstrated no such fluorescence.   
Both hSERT-expressing HEK293T and wildtype cells were subjected to a two-
step QD labeling protocol and SERT QD labeling was demonstrated by techniques 
microscopy and flow cytometry.  The representative histogram plots and heat map of the 
effects of increasing the alkyl spacer length on QD conjugate binding are shown in Figure 
6.  Comparison of control samples (QD only treated cells, Paroxetine pre-block and 
wildtype cells); the increase of average percent fluorescent intensity is closely correlated 
with the alkyl spacer length.  This correlation can also been seen in the presence of 
membrane-associated QD fluorescent labeling on the acquired microscopy images 
(Figure 4).  SavQD655 labeling of hSERT is demonstrated in stably expressing 
15 
 
HEK293T cells (Figure 4:A1 – D2) and HEK293T (Wildtype) cells (Figure :C1, C2).  
Compared to QD only control (Figure 4:A1, A2), Paroxetine pre-block competition 
(Figure 4:B1, B2), and Wild Type cells (Figure 4:C1, C2), the fluorescent intensity 
increased with hSERT-HEK293T IDT357 positively labeled cells.  A detailed depiction 
of all of the average percent fluorescent intensity values can be seen in Table and in 
Figure 7.  These data demonstrate that our QD-based approach can be used to investigate 
the length of alkyl spacer in the linker arm in a living cell assay. 
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Cyano Group Ligands
Average
Standard Error of the Mean 
(SEM)
SERT Cells 0.147 ± 0.026
SERT Cells + QD 3.086 ± 0.657
WildType + Cells 0.165 ± 0.060
WildType + QD 1.096 ± 0.314
 
SERT Cells + 
IDT596
7.384 ± 2.207
Paroxetine Preblock 
+ IDT596
3.060 ± 0.565
WildType                 
+ IDT596
12.061 ± 2.702
 
SERT Cells + 
IDT590
48.538 ± 8.610
Paroxetine Preblock 
+ IDT590
22.557 ± 11.487
WildType                 
+ IDT590
32.887 ± 6.449
 
SERT Cells + 
IDT531
42.866 ± 8.487
Paroxetine Preblock 
+ IDT531
22.386 ± 8.508
WildType                 
+ IDT531
37.810 ± 7.645
 
SERT Cells + 
IDT361
75.090 ± 3.783
Paroxetine Preblock 
+ IDT361
26.035 ± 10.383
WildType                 
+ IDT361
40.731 ± 7.888
Hydrogen Group Ligands
Average
Standard Error of the Mean 
(SEM)
SERT Cells 0.147 ± 0.026
SERT Cells + QD 3.086 ± 0.657
WildType + Cells 0.165 ± 0.060
WildType + QD 1.096 ± 0.314
 
SERT Cells + 
IDT591
6.230 ± 0.790
Paroxetine Preblock 
+ IDT591
4.295 ± 0.375
WildType                 
+ IDT591
20.750 ± 0.563
 
SERT Cells + 
IDT366
34.100 ± 5.000
Paroxetine Preblock 
+ IDT366
5.015 ± 0.455
WildType                 
+ IDT366
21.825 ± 0.891
 
SERT Cells + 
IDT579
30.150 ± 4.050
Paroxetine Preblock 
+ IDT579
6.960 ± 0.330
WildType                 
+ IDT579
29.100 ± 1.578
 
SERT Cells + 
IDT532
53.750 ± 4.846
Paroxetine Preblock 
+ IDT532
11.555 ± 4.272
WildType                 
+ IDT532
32.671 ± 9.156
 
SERT Cells + 
IDT357
73.625 ± 5.951
Paroxetine Preblock 
+ IDT357
10.898 ± 3.165
WildType                 
+ IDT357
37.936 ± 9.778
Figure 7. The table details all of the average percent fluorescent intensity values of each of 
the ligands screened. SavQD655 labeling of hSERT stably expressed in HEK293T cells and 
HEK293T (Wildtype) cells.  
3-(1,2,3,6-tetrahydropyrindin-4-
yl)-1H-indole igands 
3-(1,2,3,6-tetrahydropyridin-4-yl)-
1H-indole-5-carbonitrile Ligands 
17 
 
 
Visualization of the trend between the average percent fluorescent intensity values 
and the carbon alkyl spacer length can be seen in Figure 8.  As the carbon alkyl spacer 
length increased in both ligand models containing the 3-(1,2,3,6-tetrahydropyrindin-4-
yl)-1H-indole drug end and its cyano derivative ligand, 3-(1,2,3,6-tetrahydropyridin-4-
yl)-1H-indole-5-carbonitrile, the average percent fluorescent intensities increased 
(Figures 8: A, B).  The ideal binding length from RosettaLigand modeling predicted that 
an alkyl spacer greater than six would provide sufficient labeling (Figure 9). 
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CONCLUSION AND FUTURE DIRECTIONS 
These flow cytometry fluorescent intensity results are in good agreement with the 
trend obtained by the predictions with RosettaLigand and the RosettaScore software.  
According to the RosettaLigand calculations, as the alkyl spacer length increased in both 
ligand models, the binding affinity for the SERT protein increased, with the 6-carbon 
alkyl spacer being the minimum length to maximize binding affinity of the SERT ligand.  
Based on these findings, one can combine molecular modeling and fluorescence-based 
assays to improve ligand design and development.  
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Chapter II 
 
Quantum Dot Fluorescence-Based Drug Discovery 
 
 
A. Human Serotonin Transporter Displacement Assay 
 
 
INTRODUCTION 
Major depression is a debilitating and recurrent disorder with a substantial 
lifetime risk and a high social cost.
1
  At any given time, depression has been shown to 
affect nearly 18 million people in the United States alone.
2
 Over the past 30 years, a 
variety of studies of the serotonin (5-Hydroxytryptophan, 5-HT) system and its principal 
component, serotonin transporter (5-HT, SERT), have reinforced its significant role in 
pathophysiology of major depression.
3
  The presynaptic serotonin transporter regulates 
synaptic levels of 5-HT by recycling it into the presynaptic terminals in the brain.
4
  Low 
synaptic 5-HT levels have been shown to induce depressive symptoms, such as mood 
swings, fatigue, anxiety, and suicidal tendencies.
1
  To treat these symptoms, selective 
serotonin reuptake inhibitors (SSRIs) are widely used as clinical antidepressants.  One of 
the major drawbacks of antidepressants is the delayed onset of clinical effect, which can 
take as long as 3-6 weeks.
16
  Within the past decade, a number of new antidepressant 
agents have been developed that act on multiple targets, such as serotonin-norepinephrine 
reuptake inhibitors (SNRIs) and the serotonin-norepinephrine-dopamine reuptake 
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inhibitorsc (SNDRIs).
2
 SNRIs and SNDRIs have been reported to possess a slightly 
greater efficacy and possibly a more rapid onset of action, than SSRIs.
1
 Another 
emerging area in antidepressant drug discovery focuses on studying the primary binding 
pocket (orthosteric site) of SERT versus the secondary, allosteric binding site of the 
protein.  Currently, no crystal structure of the serotonin transporter protein is available, 
which makes validating allosteric or orthosteric antagonism difficult.
17,18
  A number of 
potent SSRIs have been proposed as allosteric modulators for SERT, such as R-
citalopram and paroxetine.
19,20
  However, the advancement in multi-target and allosteric 
antidepressant drug discovery has been inhibited by the lack of appropriate screening 
platforms.
1,18
  Currently, in vitro antidepressant drug discovery is based on 
electrophysiology, protein phosphorylation assays, and radiolabeled ligand uptake assays.  
The disadvantages of these methods include time-consuming, labor-intensive 
experimental work and safety concerns associated with isotope handling.
1 
One strategy to improve the discovery process of novel SNRIs and SNDRIs is the 
use of fluorescent probes for a target-selective drug screening.   However, there are 
numerous shortcomings when using organic fluorescent probes for drug discovery 
platforms, for instance limitations in photostability and sensitivity.  The emergence of 
semiconductor nanocrystals, also known as quantum dots (QDs), provided the unique 
photophysical properties that supplied several advantages which are needed for in vitro 
fluorescence-based studies.  QDs are nanometer-sized semiconductor nanocrystals with 
the exciton Bohr radius smaller than that of the bulk semiconductor material.
9,10
  The 
QDs size tunability of their emission spectra combined with a broad absorption spectra 
enables and considerably simplifies multiplexing simultaneous imaging of several, 
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multicolored fluorophores using a single excitation source.
9,10
  Compared to traditional 
fluorophores, the robust inorganic nature of QDs provides excellent photostability and 
brightness, which allow for long-term imaging of biological systems.
9,10
  Previously, 
research from the Rosenthal group focused on utilizing conjugated QD probes to label 
SERT in living Xenopus oocytes (frog eggs).
18 
This labeling approach used ligand-
conjugated QD probes that accessed the substrate-binding site and demonstrated a strong 
model for an in vitro drug displacement assay.  The ligand construct (IDT318) was 
designed and synthesized by Ian D. Tomlinson specifically for this study. IDT318 is 
unique in that it explicitly targets the native substrate (5-HT) binding site via tryptamine 
drug analogue.  However, a drug displacement in an amphibian model does not validate 
that the ligand-conjugated QD probe can be used in a human model system.  In this 
preliminary report, the ligand-conjugated QD labeling approach for antidepressant drug 
discovery will be applied to a cellular platform. To use the ligand-conjugated QD 
labeling approach and ultimately establish antidepressant drug discovery assay in a cell 
platform, SERT will be labeled with a two-step QD method which allows visualization of 
the SERT protein.  This labeling will result in a distinct, fluorescent signal along the 
cellular membrane.  Using a compact 96-well format, which is suitable for high-
throughput drug screening, the labeled fluorescent cells will be treated with SERT 
selective inhibitors, neurotransmitters, or other potential drug compounds.  The selective 
inhibitors or neurotransmitters, due to high affinity for SERT, will either compete for the 
protein transporters orthosteric binding site or its secondary, allosteric binding site 
(Figure 10).   
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Thus, the SERT selective inhibitor will displace the QD labeled cellular 
transporter and cause the decrease in fluorescence.  There are two possible modes in 
which the ligand-conjugated QD displacement assay can occur; which are illustrated in 
Figure 10.  The competitive mode (seen on the left) prevents the ligand re-association 
with the SERT protein primary (or orthosteric) binding site.  The allosteric mode (seen on 
the right) dissociates the ligand through an allosteric mechanism, which cause a 
conformational change to the primary binding site.  The fluorescent measurements will 
be obtained using the Perkin Elmer Opera™; a premier spinning disk confocal microplate 
imaging reader for high-throughput high content screening.  Based on these 
aforementioned studies and utilizing cellular response kinetics, selective inhibitors, 
neurotransmitters or other potential compounds affinities and drug response data will be 
obtained.  
Figure 10. Diagram of QD Based SERT displacement assay 
Fluorescence Intensity: 
High 
Fluorescence Intensity: 
Low 
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EXPERIMENTAL 
Fluorescence QD-SERT Ligand Design 
The designed ligand IDT318 is composed of four components (as depicted in Figure 11).  
The IDT318 ligand has the SERT drug analogue, 5-mthoxy-3-(1,2,5,6-tethydro-4-
pyridinyl)-1H-indole (RU24969), which was based on the study of trypamine derivatives 
and retains the tryptamine moiety for binding to the common (orthosteric) serotonin 
binding site (component A).14,18  The alkyl spacer enhances the ligand binding by 
allowing the tryptamine moiety an enhanced route to the binding sites (component B).  
The polyethylene glycol (PEG) chain increases water solubility of the linker and possibly 
decrease any nonspecific interactions (component C).  The biotinylated handle at the end 
of the PEG chain serves as the binding site for the Streptavitin-Quantum Dots 
(Streptavidin Qdot® 655, Invitrogen) (component D).   The synthetic details of the 
ligand IDT318 are described in one of our recent publications, where a brief outline is 
described below.14,18  The parent drug analogue, 5-methoxy-3-(1,2,5,6-tetrahydro-4-
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pyridinyl)-1H-indole was synthesized and coupled to 11-(1,3-Dioxo-1,3-dihydro-
isoindol-2-yl)-undecyl bromide which yields 2-(11-(4-(5-methozy-1H-indol-3yl)-5,6-
dihydropyridin-(2H)-yl)-undecyl) isoindoline-1,2-dione in the presence of triethylamine. 
The phthalimide protecting group was removed using hydrazine monohydrate to give 11-
(4-(5-methoxy-1H-indol-3-yl)-5,6-dihydropyridin-1(2H)-yl)-undecan-1-amine, which 
was then coupled to biotin-polyethylene glycol-N-hydroxysuccinimide ester.  Once the 
IDT318 has been synthesized, it can be used as ligand-conjugated probes for a target-
selective drug screening 
Cell Line Maintenance and hSERT Activity Assay 
The hSERT stably transfected HEK293T host cell line was provided by Dr. Randy 
Blakely’s lab (Vanderbilt University) and was grown in complete DMEM, supplemented 
with 10% dialyzed FBS and incubated in humidified atmosphere with 5% CO2 at 37°C.  
The SERT-expressing HEK293T cells were selected in the presence of 400 μg/mL G418. 
The SERT protein activity in living HEK293T cells was examined before each 
experiment by using IDT307, a fluorescent neurotransmitter substrate15.  IDT307 
compound is nonfluorescent in solution but fluoresces as the substrate is accumulated 
into the nucleus membrane, affording real-time evaluation of SERT uptake activity.15 The 
assay to verify successful SERT expression in HEK293T cells involves the addition of 
IDT307 directly to the culture media at a final concentration of 5 μM and incubating at 
37°C for 10 minutes. Fluorescent images were then acquired immediately after IDT307 
addition, and successful transporter expression was evident by an observable increase in 
intracellular fluorescence. 
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Labeling HEK293T Cells with Ligand-Conjugated Quantum Dots 
To visualize the SERT binding to the ligand-conjugated QD probes in a cellular 
model, a two-step labeling approach was used.  The SERT expressing stably transfected 
human SERT (hSERT) HEK-293T cell line was chosen as the stable expression system.  
The cells were grown in 96-well, poly-D-lysine coated, Perkin Elmer Cell Carrier™ 
plates in 10% dialyzed FBS DMEM media.  The stably transfected hSERT HEK-293T 
cells were treated using a two-step QD labeling protocol.  The hSERT-HEK cells were 
incubated with 0.5 μM of the IDT318 ligand in FBS free DMEM media for 10 minutes at 
37
o
C, prior to 5 minute incubation of 1 nM of SavQDs (Qdot® 655 streptavidin 
conjugate, Invitrogen).  After the SavQD655 incubation, several wash steps using fetal 
bovine serum free containing DMEM media were used to rinse away any unbound ligand 
and SavQD655s.   
Initial Confocal Fluorescent Microscopy 
The initial DIC and fluorescent images were acquired on the Zeiss Laser Scannin 
Microscope 510 inverted confocal microscope. These initial images were acquired before 
progressing to the Perkin Elmer Opera™.  The microscope excitation source was the 488 
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nm laser and used a 585 nm long pass filter (Figure 12).  Images were attained using the 
20X objective and the Zesis Plan-Apo oil immersion objective (63X), with a numerical 
aperture of 1.40.   
RESULTS AND DISCUSSION 
When the cells were labeled with the two-step, QD ligand-conjugated method, 
none of the cells demonstrate the anticipated SERT cell labeling (as seen in Figure 13).  
In fact, the experimental sample has the same amount of fluorescence as the QD only 
control (seen in Figure 13).  There is uncertainty behind the reason why there is an 
inability to label and high ligand mediated background.  A new batch of IDT318 has been 
synthesized and is currently being screened for biological functionality (see Appendix C 
for Ligand screening). 
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 As the new batch of IDT318 was being synthesized, a more potent ligand, 
IDT361, was used to fluorescently label SERT (Figure 14).  The ligand IDT361 is 
approximately one thousand times stronger and more potent than the indole ligand, 
IDT318.
14,18
  The ligand IDT361 includes a cyano derivative on the 5-position of the 
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indole ring, which allows it to bind stronger than its methoxy group analogue derivative, 
IDT318.   
This stronger binding capability of IDT361 ligand was to demonstrate and 
visualize the SERT binding to the ligand-conjugated QD probes in the cellular model 
(Figure 15); IDT361 was less likely to be readily displaced due to its higher affinity for 
the SERT binding pocket.
14,21
 The electrophysiological assay reported in Tomlinson, et. 
al., supported this by describing a current response induced by the ligands, IDT318 and 
IDT361, which correlates with the SERT binding affinities of the drug analogues.
22
  As 
indicated, the SERT binding affinity of IDT318 was found to be in low, μM affinity 
range; whereas IDT361 had an affinity in the high, nM range.  
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After the two-step labeling method, QD labeled hSERT HEK-293T cells were 
treated with different concentrations of paroxetine (Paxil®), a high affinity SERT 
specific inhibitor.  As anticipated, the IDT361 was not displaced, as the fluorescence 
intensity remained constant along the cellular membrane.  This is demonstrated in the 
time-dependent fluorescent intensity plot and images shown below (Figure 16).  The 
IDT361-conjugated QD labeled hSERT HEK-293T cells were treated with 100 μM of the 
high affinity SERT specific inhibitor, paroxetine.  Based on previous publications, the 
lower affinity IDT318 ligand-conjugated QD probe would be displaced immediately, 
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using only 10 μM of paroxetine.18  
CONCLUSION AND FUTURE DIRECTION 
To summarize, our objective is to develop a fluorescence quantum dot SERT 
displacement assay in a human cellular platform for multi-target drug discovery.  Current 
progress on the SERT displacement assay has demonstrated that using the current batch 
of IDT318 leads to the inability to label the cells as well as to a high ligand-mediated 
background.  A new batch of IDT318 has been synthesized and is currently being 
screened for biological functionality (Appendix B).  It has also been demonstrated, 
employing a more potent ligand, IDT361, while able to label the SERT protein, the 
ligand cannot be displaced using a high affinity SERT specific inhibitor. 
The biological functionality of the new batch will be demonstrated using both 
microscopy and flow cytometry techniques.  The stably transfected hSERT HEK-293T 
cells will be treated with 0.5 μM of the new batch of IDT318 ligand and 1 nM of 
Streptavidin-QD655 using the two-step labeling approach.  The control cell samples will 
be treated with only 1 nM Streptavidin-QDs without the ligand IDT318.  To test for 
ligand specificity, Paroxetine, a potent and selective serotonin reuptake inhibitor (SSRI), 
will be used to pre-block the SERT protein. Due to higher fluorescent intensities, the flow 
cytometry analysis of the ligand-conjugated QD labeled cells, compared with the control 
samples, will determine cell populations specifically labeled for the SERT protein.  After 
using flow cytometry, the fluorescent microscopy experiments will be performed by 
simply depositing an aliquot of the cell suspension onto a glass slide and imaging.  These 
approaches can be effective at demonstrating labeling of the SERT protein.   
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Once the new batch of ligand can be used to label SERT, the ligand-conjugated 
QD based displacement assay will be demonstrated in the new cellular platform.  The 
cellular displacement assay platform will be tested using SERT selective inhibitors, 
neurotransmitters, or other potential drug compounds.  This new drug discovery assay has 
the potential to aid in the discovery of new antidepressant and the mapping allosteric 
versus orthosteric mechanisms of the SERT protein.  Once the assay is well established, it 
will be transitioned to a high-throughput drug screening platform by utilizing the Perkin 
Elmer Opera™, a premier spinning disk confocal microplate imaging reader. 
 
B. Human Dopamine Transporter Medium-Throughput Flow Cytometry 
Screening Method 
 
INTRODUCTION 
Numerous analytical pharmacological assays methods have been developed to 
screen for small-molecule modulators or to determine possible target identification and 
validation of membrane proteins.  These pharmacological methodologies are often 
limited to cell-free assays, which are founded on target-based methods only involving 
purified enzymes or proteins.  These target-based approaches are often based on the 
assumption that disruption of a single enzymatic reaction or molecular mechanism is the 
key event in disease ontogeny.
23
  More recently, emphasis has been placed on cell-based 
screens using organic fluorochromes or enzymatic reporters.
24,25
 These cell-based 
systems provide an important approach for investigating quantitative dose response 
curves that can be generated for a possible high-content analysis. Moreover, cell-based 
33 
 
screens allow the investigation of multiple pathways and many cell types 
simultaneously.
24,25
  While these cell-based assays can provide more detailed data 
compared to non-cellular based assays, there are still imitations in cell-based assays.  
Pharmacological screens which focus on a single biochemical target or a single cell types 
ignore the potential of small molecules or compounds to exhibit differential behavior 
across cell types and possibly affect multiple signaling pathways.
24,25
  The inherent 
variability of cell types can impede assay design, affect assay robustness, and increase 
variability from design to design.   Even the most advanced live cell-based screens can 
create assay design issues due to multiple targets across many different cell types. 
Therefore, a fluorescence-based platform that can distinguish cell types from one 
another and simultaneously measure the effects of a drug on multiple pathways in a 
signaling network would be beneficial.
24,25
  Flow cytometry allows for a high-content 
analysis, mulitparameter investigation of a single cell type, making it a promising tool for 
drug discovery.  In these multiparameter approaches, multiple sets of data are collected in 
a single reaction some volume where each data set reports a unique diagnostic 
component.
26
  Here, we present a novel quantum dot based, medium-throughput flow 
cytometry screening method.  To demonstrate this adaptable medium-throughput 
screening (MTS) method, its properties were utilized in a pharmacological assay. 
Nanometer-sized semiconductor nanocrystals, also known as quantum dots 
(QDs), are nanotechnology’s powerful probes and offer a revolutionary fluorescence 
design.  The properties which give QDs their unique aptitudes include: photostability for 
live-cell imaging and long-term cellular studies, size-tunable color emission, single-
excitation source thereby simplifying multicolor analysis, and narrow, symmetrical 
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emission spectra for low fluorescence cross-talk.
9,10
  The possibilities are continually 
being developed for additional applications of these versatile QDs.
9
   
We have previously reported the synthesis and development of ligand-conjugated 
QD-based systems, employed in the visualization of serotonin transporter, the GABAc 
transporter, and dopamine transporter (DAT).
18,27,28
  Our labeling approach used a 
dopamine transporter with a specific drug end, 2-beta-carbomethexy-3-beta-(4-
fluorophenyl) tropane (IDT44), and biotinylated ligand, which binds to streptavidin-
conjugated quantum dots.
27
  The ligand, IDT444, utilizes a structural analogue of 
cocaine, phenyltropane-based dopamine reuptake inhibitor parent compound (beta-CFT, 
WIN 35,428); which is 3-10x more potent than cocaine and offers excellent labeling 
stability.
27
  Previously, Beta-CFT has been used in the binding of novel ligands to DAT 
and radioisotope forms of CFT have been used to map the distribution of dopamine 
transporters in the brain. 
 In developing our quantum dot based, medium-throughput flow cytometry 
screening method, our goal is to develop a highly quantitative assay, enabling dose-
response titration curves and establish a QD screening assay which had extremely high 
ability to accurately identify active drug compounds.  Furthermore, through the benefit of 
QDs, our MTS method generates a multipurpose drug screening assay that could measure 
multi-targets simultaneously and be applied towards the development of drugs beyond 
the focus of the dopamine transporter. 
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EXPERIMENTAL 
Fluorescence QD-DAT Ligand Design  
The designed ligand IDT444 is composed of four components (as depicted in 
Figure 17).  The IDT444 ligand has the DAT antagonist, 2-β-carbomethoxy-3-β-(4-
fluorophenyl)tropane, which was based on a cocaine analogue  (component A).  The alkyl 
spacer enhances the ligand binding by allowing the cocaine analogue access to the 
binding sites (component B).  The polyethylene glycol (PEG) chain increases water 
solubility of the linker and possibly decrease any nonspecific interactions (component C).  
The biotinylated handle at the end of the PEG chain serves as the binding site for the 
Streptavitin-Quantum Dots (Streptavidin Qdot® 655, Invitrogen) (component D).  The 
synthetic details of the ligand IDT444 are described in one of our recent publications.27 
Cell Line Maintenance and hDAT Activity Assay 
To visualize the DAT binding to the ligand-conjugated QD probes in a cellular 
model, a two-step labeling approach was used.  The DAT expressing stably transfected 
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human DAT (hDAT) HEK Flp-In-293 cell line was chosen as the stable expression 
system (obtained from Dr. Randy Blakely’s Lab, Vanderbilt University).  The cells were 
grown in complete medium DMEM with L-glutamine, 10% FBS, and 1% penn/strep.  
The DAT-expressing Flp-In-293 cells were selected in the presence of 100 μg/mL 
hygromycin B. 
Labeling HEK293T Cells with Ligand-Conjugated Quantum Dots for Confocal 
Fluorescent Microscopy 
 The stably transfected hDAT-expressing HEK Flp-In-293 cells were treated 
using a two-step QD labeling protocol.  Previously before imaging experiments, DAT-
expressing HEK Flp-In-293 cells were seeded in MatTek (MetTek Corporation) 
polylysine-coated plates and were allowed to grow for approximately 48 hours at 37
o
C 
and 5% CO2. 
Stably transfected hDAT-expressing HEK Flp-In-293 cells were incubated 37
o
C 
and 5%CO2 for 10 minutes with 100nM of IDT444.  Following the ligand incubation, the 
cells were washed with warm DMEM free media.  Once washed, HEK cells were 
incubated at 37
o
C and 5%CO2 for 5 minutes with 1 nM of SavQD655 plus 1%BSA 
mixture (Qdot® 655 streptavidin conjugate, Invitrogen).  After the SavQD655 labeling 
step, HEK cells were washed with DMEM free media to remove any unbound SavQD655 
and cells images were acquired on the Zeiss Laser Scanning Microscope 510 inverted 
confocal microscope.  Images were attained using the 20X objective and the Zesis Plan-
Apo oil immersion objective (63X), with a numerical aperture of 1.40.   
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Labeling HEK Flp-In-293 Cells with Ligand-Conjugated Quantum Dots for Flow 
Cytometry 
 The stably transfected hDAT-expressing HEK Flp-In-293 cells were treated 
using a two-step QD labeling protocol (Figure 18).  Prior flow cytometry experiments, 
DAT-expressing HEK Flp-In-293 cells were seeded in 24-well polylysine-coated plates 
(BD Bioscience®) and were allowed to grow for approximately 48 hours. 
HEK Flp-In-293 cells were washed with warm KRH buffer and incubated with 
GBR12909, high-affinity DAT antagonist, for 20 minutes at 37oC and 5% CO2.  HEK 
cells were then washed again with KRH buffer and incubated at room temperature for 10 
minutes with equal parts IDT444 plus GBR12909 in desired concentration mixture or 
only IDT444 of desired concentration.  Following the ligand/drug incubation, the cells 
were washed with KRH buffer.  Once washed, HEK cells were incubated at RT for 5 
minutes with 1nM of SavQD655 plus 1%BSA mixture (Qdot® 655 streptavidin 
conjugate, Invitrogen).  After the SavQD655 labeling step, HEK cells were washed with 
KRH to remove any unbound SavQD655 and cells were nonenzymatically dissociated 
from the 24-well polylysine-coated plates using CellStripper (Mediatech Inc.) and 
transferred to polystyrene disposable tubes (BD Bioscience® Falcon tubes). 
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Flow Cytometry 
All samples were analyzed on a BD LSRII flow cytometer and the SavQD655 
fluorescence was excited at 488-nm excitation laser. Ten thousand events were collected 
per sample and the median fluorescence intensity (MFI) values were determined for the 
gated cell fluorescence populations using FlowJo (Tree Star). 
RESULTS AND DISCUSSION 
 To summarize, our objective is to develop a human dopamine transporter 
medium-throughput flow cytometry screening assy.  Our assay utilizes DAT antagonist-
conjugated QDs to assay DAT activity and regulation in live cells in a multi-well plate 
platform.  
Visualization of hDAT HEK293 cells fluorescently labeled with DAT ligand, 
IDT444 and SavQD655 can be seen in Figure 19.  Fluorescent intensities IDT444 Flip In 
hDAT HEK293 cells positively labeled cells at 20x (B1, B2) and 63x (A1, A2) 
magnification.  Fluorescent (right) and DIC (right) images are shown.  Once fluorescent 
labeling had been demonstrated in the cell line model, the assay’s signal dynamic range 
and evaluation of the quality of this platform, a Z’ statistical factor was determined using 
only the control data as follows: 
𝑍′ =  1 − 
(3𝜎𝐶+ +  3𝜎𝐶−) 
|𝜇𝐶+ − 𝜇𝐶+|
 
Equation 1: Z’ statistical factor 
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The Z’-factor takes into account the signal-to-noise ratio and s.d. of control samples and 
is commonly utilized for quality assessment in assay development. Values of Z’ ≥ 0.5 are 
considered excellent.29 The Z’-factor of our QD-based assay was determined to be 0.73, 
indicating the structure of the assay is of high quality (Figure 20). 
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Once the assay validity and quality was determined by the calculated Z’-factor, a 
series of experiments using a known high-affinity DAT antagonist were performed to 
evaluate the assay effectiveness. Adherent human DAT-expressing HEK Flp-In-293 cells 
were exposed to varying GBR12909 antagonist doses. The median fluorescence intensity 
(MFI) measured by flow cytometry was used to estimate percent inhibition (PI) of QD 
conjugate binding according to the equation below: 
  =   
      −            
      −        
  1    
Equation 2: Percent Inhibition (PI) 
 
The obtained PI data were pooled from three independent experiments with triplicate 
samples to generate a dose-response curve (Figure 21). The half-maximal inhibitory 
concentration (IC50) of GBR12909 was determined to be 27 ± 7 nM, which is in excellent 
agreement with values obtained using conventional techniques. Typical IC50 values 
reported for inhibition of [3H]DA transport are in the 1-50 nM range for GBR12909.30 
Together, these experiments demonstrated that our QD-based platform could be used to 
accurately predict inhibitory activity of DAT antagonist and possibly be used as 
alternatives for current drug discovery assays. 
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CONCLUSION AND FUTURE DIRECTIONS 
The QD-based flow cytometric assay was used to accurately measure inhibitory 
action of known high-affinity DAT antagonist, GBR12909. The Z’-factor, a statistical 
measure of assay quality and performance, was calculated to be 0.73, which is an 
“excellent” rating for Z’-factor.  Development of fluorescence-based binding assays that 
target human cell surface proteins with unresolved crystal structures and ineffective 
antibodies against the extracellular epitope is particularly challenging.8  Here, we 
presented a platform that addresses these issues and could be used as alternative for 
current drug discovery assays which utilize radioactive materials. Our QD-based assay 
may also be of potential value to high-throughput of small-molecule neuromodulators of 
the dopamine transporter, as it can easily employ 384-well plates. In addition, broad 
absorption and narrow emission spectra of QDs will allow monitoring of several targets 
or cellular responses and may therefore establish pathway and cell-type selectivity of 
DAT modulators in a high-content screen.8,24,25   
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Chapter III 
 
Development of a Quantum Dot-Based Fluorescent Somatostatin Receptor Probe 
 
INTRODUCTION 
Somatostatin (SST or SST-14) and the SST receptors (SSRTs) are broadly 
expressed in the human body where they exert many physiological actions, such as 
regulating insulin release to modifying the central neural control of blood pressure and 
breathing.
31-33
 The peptide neurotransmitter and hormone somatostatin and the 
somatostatin receptors (which includes subtypes SSTR1-SSTR5) have been implicated as 
playing a prominent role in epilepsy.  This hypothesis is based on persuasive 
experimental observations: (1) activity-dependent release of SST peptide during seizures; 
(2) the modulation of SST mRNA expression, peptide levels and receptors by seizures; 
(3) the effect of SST and its analogues on seizures in mouse models.
31-35 
In most studies addressing tissue or cell localization and trafficking of the 
somatostatin receptors, radioactively labeled SST peptide complexes were employed.  
The intrinsic resolution limit of the radiolabeling approaches precludes capturing these 
processes with a sufficient level of morphological, functionality, and biomolecular 
detail.
36 
Questions about the somatostatin system which remain unresolved: 
1. Many approaches have been limited and restricted to labeling SST receptors by 
immunofluorescence techniques.  The literature has not begun to explore the labeling 
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SST ligands and understanding the fate (post-endocytosis) of the peptides in vitro and 
comparing certain cell types. 
2. Currently, the literature has not begun to explore the localization, trafficking, and 
understanding the fate of SST receptors with in an in vitro neuronal cells model.  This 
neuronal cell model system would utilize whole cell patch-clamp to induce seizures 
versus normal neuronal cells.   
3. At present, only limited knowledge exists regarding specific interacting proteins 
which modulate the differential intracellular trafficking of somatostatin receptors.  There 
are big questions remaining about the molecular mechanisms underlying dimerization of 
the SST protein receptors.  It is still debatable if SSTR subunits fit the two general G 
protein-coupled receptor models (GPCR).  Fluorescence tracking data would provide a 
new level of understanding in the functioning of human SSTRs and may help elucidate 
the functional properties of GPCR proteins. 
Developing and synthesizing a Quantum Dot Somatostatin fluorescence probe 
would allow us to understand the behavior of the somatostatin receptor subtypes in terms 
of agonist-induced internalization and receptor interaction and consequently identify 
somatostatin receptors that should be targeted for future therapeutics.   
The emergence of semiconductor nanocrystals, also known as quantum dots 
(QDs), provided the unique photophysical properties that supplied several advantages 
which are needed for in vitro fluorescence-based studies.  QDs are nanometer-sized 
semiconductor nanocrystals with the exciton Bohr radius smaller than that of the bulk 
semiconductor material.
9,10
  The QDs size tunability of their emission spectra combined 
with a broad absorption spectra enables and considerably simplifies multiplexing 
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simultaneous imaging of several, multicolored fluorophores using a single excitation 
source.
9,10
  Compared to traditional fluorophores, the robust inorganic nature of QDs 
provides excellent photostability and brightness, which allow for long-term imaging of 
biological systems.
9,10
  
By developing and synthesizing a QD somatostatin probe, long-term live-cell 
imaging can be performed which would allow us to understand the behavior of the 
somatostatin receptor subtypes in terms of agonist-induced internalization and receptor 
interaction and consequently identify somatostatin receptors that should be targeted for 
future therapeutics.  Understanding the function of the peptide neurotransmitter/hormone 
SST and the Somatostatin Receptors (SSTR1-SSTR5), will provide information for 
clinical therapy for epilepsy, neuroendocrine and metabolic disorders (such as 
neuroendocrine tumors), retinal disease, and possible medical treatment of schizophrenia 
disorder.
31-36 
EXPERIMENTAL 
Materials 
Rink amide resin and Fmoc-protected amino acids, hydroxybenzotriazole (HOBt), 
2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU), 
were purchased from Aapptec or AnaSpec. Piperidine, trifluoroacetic acid (TFA), 
Acetonitrile (HPLC grade), dry diethyl ether, Thioanisole, Ethanedithiol (EDT), Anisole 
were purchased from Sigma-Aldrich.  
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Direct Solid Peptide Synthesis of Somatostatin-14 
 
 
Direct solid peptide synthesis of Somatostatin-14 (SST-14) probe was done as 
described by Jean E. F. Rivier (1974) and Applied Biosystems Technical Bulletin with 
slight modifications. The sequence of SST-14 was synthesized on Rink amide resin.  
Resin (0.70 mmol/g) was washed three times with approximately 2 mL of DMF in 
reaction vessel before starting the synthesis.  Coupling was performed by dissolving the 
Fmoc-protected amino acid with HOBt, HBTU, and DIEA in DMF. After 5 min, the 
amino acid solution was added to the Rink amide resin and left for 2 hours at 25 
o
C with 
continuous swirling. After the final Fmoc deprotection with 20% piperidine in DMF and 
wash procedure (with DMF, methanol and DMF), the resin complex was dried for 
deprotection and resin cleavage. 
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The peptide side chain deprotection and resin cleavage were carried out in 
Reagent R solution (containing 9.0 mL TFA, 0.5 mL thioanisole, 0.3 mL EDT, and 0.2 
mL Anisole) and gently stirred for 2 hours at 25 
o
C.  The peptide was precipitated by 
addition of ice-cold dry ether, after the removal of Reagent R solution by glass wool 
filtration. The precipitate was washed with cold ether and lyophilized to white powder.  
The molecular weight of crude peptide was checked by Matrix-assisted laser 
desorption/ionization-TOF (MALDI-TOF) and is then purified. 
High-Performance Liquid Chromatography (HPLC) Purification 
Purification of the SST-14 probe used a reversed-phase C18 HPLC column. First, 
an analytical column was used to establish the major peaks, followed by a crude 
preparation or purification column.  The 1 mL of crude peptide (~1 mg/mL)  was injected 
into the HPLC column and eluted with a linear gradient of acetonitrile (from 1% to 80% 
in 60 min) in 0.1% trifluoroacetic acid (TFA).  Peaks were collected at each minute mark 
between 15 min – 35 min and frozen at -20 oC for later use. When needed, the frozen 
samples were lyophilized to white powder (if any).   
Liquid Chromatography-Electrospray Ionization-Mass Spectrometry (LC-ESI MS) 
After the purified HPLC samples were lyophilized, the exact mass of the SST-14 
peptide probe was analyzed using Liquid Chromatography-Electrospray Ionization-Mass 
Spectrometry.  The molecular weights of SST-14 probe as well as the purchased SST-14 
control from AnaSpec were analyzed.  
Ellman’s Assay 
The Ellman’s assay was utilized to verify if the disulfide bond had been formed in 
the SST-14 peptide probe.  In the Ellman’s assay, free sulfhydryl groups may be 
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estimated in the sample by comparing to a cysteine standard.  The procedure for 
quantitation sulfhydryl groups using a cysteine standard measured at an Absorbance at 
412nm and was done as described by Thermo Scientific Ellman’s Assay Kit.  
RESULTS AND DISCUSSION 
The designed somatostatin probe is composed of three components (as depicted in 
Figure 23).  The SST-14 probe has the Somatostatin peptide, H-Ala-Gly-Cys-Lys-Asn-
Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (cyclic, Cys3, Cys14), which was found to 
bind to the Somatostatin Receptors (which includes all five subtypes, SSTR1-SSTR5) 
(component A).  The Lysine spacer enhances the probe binding by allowing the SST-14 
peptide an enhanced route to the Somatostatin receptor binding sites as well as allowing 
the biotinylated end of the spacer to reach the streptavitin binding pocket (component B).  
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The biotinylated handle at the alanine end of the peptide serves as the binding site for the 
Streptavitin-Quantum Dots (Streptavidin Qdot® 655, Invitrogen) (component C).   
A schematic representation of the two proposed somatostatin-14, Streptavidin-
Quantum Dot probes are depicted in Figure 24.   
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Based on the literature it was found that the biotin is buried quite deeply inside 
the streptavidin barrel with the carboxylate oxygens and the ureido-ring nitrogen 
involved in carboxyl-transfer reactions protruding to the outside. This suggests limits to 
the nature of conjugating groups for biotin labels used in streptavidin assays.
37-39
  The 
Somatostatin-14-Biotin would most likely not provide the needed length for the biotin to 
reach inside of the streptavidin binding pocket.  Therefore, only one of the two proposed 
SST-14 Streptavidin Quantum Dot probe, Somatostatin-14-Lys(Biotin), was synthesized 
by direct solid peptide synthesis (Figure 23) 
The 1 mL of crude peptide (~1 mg/mL) was injected and purification of the SST-
14 probe used a reversed-phase C18 HPLC column.  An analytical column was used to 
establish the major peak(s), followed by a crude preparation or purification column.  The 
main peak for both synthesized SST-14 and the Somatostatin-14-Lys(Biotin) probe was 
seen at ~29 minutes.  The main peak in the experimental samples match the control 
Somatostatin-14 sample purchased from the company AnaSpec. Optical ultraviolet (UV) 
absorbance of peptides and peptide probes were measured at 280 nm.  At this 
wavelength, the absorbance of peptide is mainly due to the amino acids tryptophan and 
phenylalanine (see example of UV absorbance in Figure 24).   
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 After the purified HPLC samples were lyophilized, the exact mass of the 
purchased Somatostatin -14 control from AnaSpec, SST-14 peptide, and Somatostatin-
14-Lys(Biotin) probe were analyzed using Liquid Chromatography-Electrospray 
Ionization-Mass Spectrometry (LC-ESI MS) in Figures 25 and 26.  The predicted 
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molecular weights for Somatostatin -14 control from AnaSpec and SST-14 peptide was 
found to be 1637.88 and the molecular weight Somatostatin-14-Lys(Biotin) probe was 
projected  to be 1990.89 using the software program ChemDraw (PerkinElmer). Once 
analyzed using LC-ESI MS, molecular weights for Somatostatin -14 control from 
AnaSpec and SST-14 peptide was found to be 1637.71 and 1637.76 respectively.  The 
molecular weight Somatostatin-14-Lys(Biotin) probe found to be 1991.97, which would 
probably be characteristic of addition of a hydrogen cation and denoted [M + H]
+
. 
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The Ellman’s assay was utilized to verify if the disulfide bond had been formed in 
the SST-14 peptide and Somatostatin-14-Lys(Biotin) probe (see Figure  27).  In the 
Ellman’s assay, free sulfhydryl 
groups may be estimated in the 
sample by comparing to a cysteine 
standard (see Figure 28).  The 
procedure for quantitation 
sulfhydryl groups using a cysteine 
standard was done as described by 
Thermo Scientific Ellman’s Assay 
Kit. Both of the synthesized 
peptide and probe free sulfhydryl 
groups were compared to the purchased Somatostatin -14 control from AnaSpec.  Results 
of Ellman’s assay can be seen in Table 1.  The purchased Somatostatin -14 control from 
AnaSpec had a 
very low 
percentage of 
free sulfhydryl 
groups 
(approximately 
6%) however, 
synthesized 
SST-14 
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peptide and Somatostatin-14-Lys(Biotin) probe was found to have approximately 33% 
and 40% respectively.  Thus, it is obvious that an oxidation-step needs to be incorporated 
into the synthesis protocol to increase a complete and better yield.  
CONCLUSION AND FUTURE DIRECTIONS 
A Somatostatin-14-Lys(Biotin) probe to be used for QD labeling experiments was 
designed and synthesized.  Before cellular testing was performed using transient 
transfected human somatostatin receptor 2A HEK293T cells, an article from Andrei V. 
Zvyagin lab was published in Nanomedicine.
40
  The author’s group report, for the first 
time, on the development of a quantum dot (QD)-based fluorescent somatostatin probe 
that enables specific targeting of somatostatin receptors. Receptor-mediated endocytosis 
of SSTR was imaged using this probe.  Once news of the article came to our attention, 
the Quantum Dot Somatostatin fluorescence probe project was discontinued; there is still 
opportunity for future studies of fluorescence tracking and localization studies of the 
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somatostatin receptor subtypes in terms of agonist-induced internalization and receptor 
interactions.  
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APPENDIX A 
 
Ligand IDT567, IDT571, and IDT576 Screening Process 
 
INTRODUCTION 
 The screening process of ligands: IDT567, IDT571, and IDT576 which contained 
PEG linkers of 4, 12, and 24 respectively (Figure A-1).  The three ligands were 
synthesized and no further purification methods were completed (such as High-
Performance Liquid Chromatography) and molecular weight was never verified by 
Matrix-Assisted Laser Desorption/Ionization (MALDI). 
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EXPERIMENTAL 
Cell Line Maintenance and hSERT Activity Assay 
 The hSERT stably transfected HEK293T host cell line was provided by Dr. 
Randy Blakely’s lab (Vanderbilt University) and was grown in complete DMEM, 
supplemented with 10% dialyzed  FBS and incubated in humidified atmosphere with 5% 
CO2 at 37°C.  The SERT-expressing HEK293T cells were selected in the presence of 400 
μg/mL G418. 
The SERT protein activity in living HEK293T cells was examined before each 
experiment by using IDT307, a fluorescent neurotransmitter substrate.
15
  IDT307 
IDT567 
IDT571 
IDT576 
Figure A-1. Ligands IDT567, IDT571, and IDT576  
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compound is nonfluorescent in solution but fluoresces as the substrate is accumulated 
into the nucleus membrane, affording real-time evaluation of SERT uptake activity.
15
  
The assay to verify successful SERT expression in HEK293T cells involves the addition 
of IDT307 directly to the culture media at a final concentration of 5 μM and incubating at 
37°C for 10 minutes. Fluorescent images were then acquired immediately after IDT307 
addition, and successful transporter expression was evident by an observable increase in 
intracellular fluorescence. 
IDT307 Fluorescent Assay 
 A 24-well plate was coated with a solution of 0.1% poly-D-lysine.  Both hSERT 
stably transfected HEK293T and HEK293T Wildtype or Sham cells were seeded and 
grown for 24-48 hours in the 24-well plate until the cells reached a confluence of ~80%.  
Solutions of IDT567, IDT571, and IDT576 and paroxetine of varying concentrations (0–
10μM) were prepared by dilution with DMEM-free media (see Figure A-2). Original 
growth media was aspirated and experimental solutions were added 0.5 mL for each well 
and incubated for 15 min.  Following experimental solution incubation, 5 μM IDT307 
was injected into the wells and allowed to incubate for another 10 min.  The plate was 
removed, the media aspirated, and 0.5 
mL of fresh DMEM-free was added.  
The cells were then taken to the 
fluorescence microscope and images 
were taken at 20x optical zoom.   
Figure A-2. A sample 24-well plate.  Values across 
the top represent the concentration of drug (IDT318 or 
paroxetine) added to each well.  Images were taken 
one row at a time to maintain consistency in drug 
exposure over the course of the experiment. 
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Labeling HEK293T Cells with Ligand-Conjugated Quantum Dots for Flow 
Cytometry 
The stably transfected hSERT-expressing HEK293T cells were treated using a 
two-step quantum dot, Qdot® 655 streptavidin conjugate (Invitrogen
TM
), labeling 
protocol.  Previously before flow cytometry experiments, SERT-expressing HEK293T 
cells were seeded in 24-well polylysine-coated plates (BD Bioscience®) and were 
allowed to grow for approximately 48hours at 5% CO2 / 37°C.  Next, a flow cytometry-
based probe screening protocol was established that would allow multi-well plate 
screening of both adherent and suspension cell cultures using our ligand-conjugated 
SavQDs. Adherent SERT-expressing (1) competition control cells were pre-blocked by 
exposure to 10 μM of Paroxetine, a potent and selective serotonin reuptake inhibitor 
(SSRI), and incubated for 10 minutes at 5% CO2 / 37°C, (2) competition control, 
wildtype, and positive cells were incubated with 0.5μM SERT ligands with inhibitor 
mixture for 10 min for all sample types, (3) washed several times with DMEM free media 
and incubated with 1 nM SavQD655/1% BSA (bovine serum albumin) mixture, (4) 
nonenzymatically  dissociated (Cellstripper™), and (5) assayed by flow cytometry.   
RESULTS 
IDT307 Fluorescent Assay 
 In the fluorescence assay, all three ligands demonstrated the ability to pre-block 
IDT307 (Figure A-3), a fluorescent neurotransmitter substrate, in concentrations as low 
as 0.1 μM.  It would not be reasonable to assume the pre-blocking ability is solely due to 
the capability of the IDT ligands.  Due to the fact that the drug end of the ligand, 3-
(1,2,3,6-tetrahydropyrindin-4-yl)-1H-indole, as an IC50 approximately 0.7 uM,
22
 such 
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strong binding would probably not be exclusively contributed to the ligands.  To check 
this theory, all three ligands were used in the experiment, labeling HEK293T Cells with 
ligand-conjugated quantum dots for flow cytometry. 
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Labeling HEK293T Cells with Ligand-Conjugated Quantum Dots for Flow 
Cytometry 
 No specific fluorescence labeling was seen using flow cytometry and microscopy 
images.  The only fluorescence both flow cytometry and microscopy images 
demonstrated was non-specific QD aggregation (see Figures A-4).   
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 DISCUSSION 
 Even though no specific labeling was seen with the ligands IDT567, IDT571, and 
IDT576 which contained PEG linkers of 4, 12, and 24 respectively, this does not imply 
short PEG linkers will not work for future labeling techniques. Rather the lack of labeling 
is possible due to unknown impurities or synthetic inconsistencies.   
QD Only 
5.16% 
Stably  
Transfected 
10.7% 
Wild Type  
(no SERT) 
IDT567 
+ QD 
20.8% 
IDT571 
+ QD 
21.7% 
IDT571 
+ QD 
IDT576 
+ QD 
4.05% 
IDT576 
+ QD 
9.07% 
28.2% 
IDT567 
+ QD 
Stably  
Transfected 
Figure A-4 
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APPENDIX B 
 
IDT318 Synthesized July 22, 2011 Screened Sept.-Oct., 2011 
 
INTRODUCTION 
 The ligand IDT318 were synthesized and “purification” methods were completed 
by the ligand passing through a Milipore 3000K column however, High-Performance 
Liquid Chromatography and molecular weight was verification via Matrix-Assisted Laser 
Desorption/Ionization (MALDI) was never used. 
EXPERIMENTAL 
Cell Line Maintenance and hSERT Activity Assay 
The hSERT stably transfected HEK293T host cell line was provided by Dr. 
Randy Blakely’s lab (Vanderbilt University) and was grown in complete DMEM, 
supplemented with 10% dialyzed  FBS and incubated in humidified atmosphere with 5% 
CO2 at 37°C.  The SERT-expressing HEK293T cells were selected in the presence of 
400 μg/mL G418. 
The SERT protein activity in living HEK293T cells was examined before each 
experiment by using IDT307, a fluorescent neurotransmitter substrate.
15
  IDT307 
compound is nonfluorescent in solution but fluoresces as the substrate is accumulated 
into the nucleus membrane, affording real-time evaluation of SERT uptake activity.
15
  
The assay to verify successful SERT expression in HEK293T cells involves the addition 
of IDT307 directly to the culture media at a final concentration of 5 μM and incubating at 
37°C for 10 minutes. Fluorescent images were then acquired immediately after IDT307 
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addition, and successful transporter expression was evident by an observable increase in 
intracellular fluorescence. 
IDT307 Fluorescent Assay 
 A 24-well plate was coated with a solution of 0.1% poly-D-lysine.  Both hSERT 
stably transfected HEK293T and HEK293T Wildtype (or Sham cells) were seeded and 
grown for 24-48 hours in the 24-well plate until the cells reached a confluence of ~80%.  
Solutions of IDT318 and paroxetine of varying concentrations (0–10μM) were prepared 
by dilution with DMEM-free media (see Figure B-1). Original growth media was 
aspirated and experimental solutions were added 0.5 mL for each well and incubated for 
15 min.  Following experimental solution incubation, 5 μM IDT307 was injected into the 
wells and allowed to incubate for another 10 min.  The plate was removed, the media 
aspirated, and 0.5 mL of fresh DMEM-free was added.  The cells were then taken to the 
fluorescence microscope and images were taken at 20x optical zoom.   
Labeling HEK293T Cells with Ligand-Conjugated Quantum Dots for Flow 
Cytometry 
The stably transfected hSERT-expressing HEK293T cells were treated using a 
two-step quantum dot, Qdot® 655 
streptavidin conjugate (InvitrogenTM), 
labeling protocol.  Previously before 
flow cytometry experiments, SERT-
expressing HEK293T cells were 
seeded in 24-well polylysine-coated 
plates (BD Bioscience®) and were 
Figure B-1 sample 24-well plate.  Values across the top 
represent the concentration of drug (IDT318 or paroxetine) 
added to each well.  Images were taken one row at a time to 
maintain consistency in drug exposure over the course of the 
experiment. 
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allowed to grow for approximately 48hours at 5% CO2 / 37°C. 
Next, a flow cytometry-based probe screening protocol was established that 
would allow multi-well plate screening of both adherent and suspension cell cultures 
using our ligand-conjugated SavQDs. Adherent SERT-expressing (1) competition control 
cells were pre-blocked by exposure to 10 μM of Paroxetine, a potent and selective 
serotonin reuptake inhibitor (SSRI), and incubated for 10 minutes at 5% CO2 / 37°C, (2) 
competition control, wildtype, and positive cells were incubated with 0.5μM SERT 
ligands with inhibitor mixture for 10 min for all sample types, (3) washed several times 
with DMEM free media and incubated with 1 nM SavQD655/1% BSA (bovine serum 
albumin) mixture, (4) nonenzymatically  dissociated (Cellstripper™), and (5) assayed by 
flow cytometry.   
RESULTS 
IDT307 Fluorescent Assay 
 In the fluorescence assay, the ligand demonstrated the ability to pre-block 
IDT307, a fluorescent neurotransmitter substrate, in concentrations around 1 μM (Figure 
B-2).  Due to the fact that the ligand, IDT318, as an IC50 of 3.4 uM,18,21 it was possible 
that the IDT318 ligand was binding to the SERT protein.  To check this theory, all three 
ligands were used in the experiment, labeling HEK293T Cells with ligand-conjugated 
quantum dots for flow cytometry. 
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Figure B-2 
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Labeling HEK293T Cells with Ligand-Conjugated Quantum Dots for Flow 
Cytometry 
 No specific fluorescence labeling was seen using flow cytometry and microscopy 
images.  The only fluorescence both flow cytometry and microscopy images 
demonstrated was non-specific QD aggregation (see Figures B-3 and B-4).   
  
Flow Data 
5.10% 
47.8% 
58.8% 
Wild Type HEK293T Cells 
0.5 uM of new batch (7/22/2011) IDT318 + 1 nM QDots 
Stably Transfected hSERT HEK293T Cells 
0.5 uM of new batch (7/22/2011) IDT318 + 1 nM QD 
Stably Transfected hSERT HEK293T Cells 
1 nM QD Only 
20x All Equally Contrasted  
Figure B-3 
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Stably Transfected hSERT HEK293T Cells 
1uM of new batch (7/22/2011) 0.5 uM IDT318 + 1 nM QD 
Stably Transfected hSERT HEK293T Cells 
1 nM QDots only 
100x 
100x 
IDT318 
QD only 
All Equally Contrasted  
20x 
IDT318 
Stably Transfected hSERT HEK293T Cells 
1uM of new batch (7/22/2011) 0.5 uM IDT318 + 1 nM QD 
Figure B-4 
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DISCUSSION 
 No specific labeling was seen with the new batch of IDT318 and only non-
specific binding was demonstrated. 
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APPENDIX C 
 
Preliminary PerkinElimer Opera Imaging 
 
INTRODUCTION 
 Initial fluorescent visualization using PerkinElimer Opera of the dopamine 
transporter (DAT) protein in stably expressing Flp-In-293 cells with a custom-made, 
DAT specific biotinylated ligand, 2-β-carbomethoxy-3-β-(4-fluorophenyl)tropane 
(IDT444) that are bound by streptavidin-conjugated quantum dots.   
EXPERIMENTAL 
Cell Line Maintenance and hDAT Activity Assay 
To visualize the DAT binding to the ligand-conjugated QD probes in a cellular 
model, a two-step labeling approach was used.  The DAT expressing stably transfected 
human DAT (hDAT) HEK Flp-In-293 cell line was chosen as the stable expression 
system (obtained from Dr. Randy Blakely’s Lab, Vanderbilt University).  The cells were 
grown in complete medium DMEM with L-glutamine, 10% FBS, and 1% penn/strep.  
The DAT-expressing Flp-In-293 cells were selected in the presence of 100 μg/mL 
hygromycin B. 
Labeling HEK293T Cells with Ligand-Conjugated Quantum Dots for Confocal 
PerkinElimer Opera  
The stably transfected hDAT-expressing HEK Flp-In-293 cells were treated using 
a three-step QD labeling protocol.  Previously before imaging experiments, DAT-
expressing HEK Flp-In-293 cells were seeded in 96-well, poly-D-lysine coated, Perkin 
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Elmer Cell Carrier™ plates and were allowed to grow for approximately 24 hours at 
37
o
C and 5% CO2. 
Stably transfected hDAT-expressing HEK Flp-In-293 cells were incubated with 5 
μM of IDT307 at 37oC and 5%CO2 for 10 minutes.  After the fluorescent dye incubation, 
the cells were incubated again at 37
o
C and 5%CO2 for 10 minutes with 100nM of 
IDT444. Following the ligand incubation, the cells were washed with warm DMEM free 
media.  Once washed, HEK cells were incubated at 37
o
C and 5%CO2 for 5 minutes with 
1 nM of SavQD655 plus 1%BSA mixture (Qdot® 655 streptavidin conjugate, 
Invitrogen).  After the SavQD655 labeling step, HEK cells were washed with DMEM 
free media to remove any unbound SavQD655 and cells images were acquired on the 
Perkin Elmer Opera™; a premier spinning disk confocal microplate imaging reader for 
high-throughput high content screening. 
RESULTS 
 The Perkin Elmer Opera™ appears to be a successful microscope imaging the 
dopamine transporter (DAT) protein in stably expressing Flp-In-293 cells with the 
IDT444 ligand bound by streptavidin-conjugated quantum dots (Figure C-1).   
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DISCUSSION 
  The Perkin Elmer Opera™ is a good microscope for imaging when there is 
efficacious ligand labeling. 
 
 
 
\ 
 
 
 
Figure C-1 
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